The Fate of Residual Tumor Masses That Persist After Stereotactic Body Radiotherapy for Solitary Lung Nodules: Will They Recur?

Clinical Lung Cancer

Volumn 17, Issue 5, 2016, Pages 406-411

  Takenaka, Ran ^a,b   Shibamoto, Yuta ^b   Miyakawa, Akifumi ^c   Hashizume, Chisa ^d   Baba, Fumiya ^e  

^a Narita Memorial Hospital   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c Department of Cardiovascular Surgery   (Japan)

^d Nagoya Kyoritu Hospital   (Japan)

^e Nagoya City University West Medical Center   (Japan)

Author keywords

Local recurrence; Residual mass; SBRT; Shrinkage; Stereotactic radiotherapy

Indexed keywords

ADULT; AGED; BASAL CELL CARCINOMA; CANCER CONTROL; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL OUTCOME; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FEMALE; HUMAN; LINEAR ACCELERATOR; LUNG ADENOCARCINOMA; LUNG EMPHYSEMA; LUNG METASTASIS; LUNG NODULE; MALE; MINIMAL RESIDUAL DISEASE; NON SMALL CELL LUNG CANCER; RECURRENCE RISK; SQUAMOUS CELL LUNG CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME; VERY ELDERLY; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; RADIATION PNEUMONIA; RADIOSURGERY; RETROSPECTIVE STUDY; SOLITARY PULMONARY NODULE; TIME FACTOR; TUMOR RECURRENCE; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PULMONARY EMPHYSEMA; RADIATION PNEUMONITIS; RADIOSURGERY; RETROSPECTIVE STUDIES; SOLITARY PULMONARY NODULE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84953432624     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.12.003     Document Type: Conference Paper

References (47)

1. 1 Nagata, Y., Negoro, Y., Aoki, T., et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 52 (2002), 1041–1046.
2. 2 Onishi, H., Araki, T., Stereotactic body radiation therapy for stage I non-small-cell lung cancer: a historical overview of clinical studies. Jpn J Clin Oncol 43 (2013), 345–350.
3. 3 Siva, S., MacManus, M., Ball, D., Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 5 (2010), 1091–1099.
4. 4 Timmerman, R., Paulus, R., Galvin, J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303 (2010), 1070–1076.
5. 5 Uematsu, M., Shioda, A., Suda, A., et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 51 (2001), 666–670.
6. 6 Chang, J.Y., Senan, S., Paul, M.A., et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized trials. Lancet Oncol 16 (2015), 630–637.
7. 7 Matsuo, Y., Chen, F., Hamaji, M., et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer 50 (2014), 2932–2938.
8. 8 Samuels, M.A., Kandula, S., Koru-Sengul, T., et al. Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. Clin Lung Cancer 14 (2013), 446–451.
9. 9 Sandhu, A.P., Lau, S.K., Rahn, D., et al. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer 15 (2014), 131–135.
10. 10 Shintani, T., Masago, K., Takayama, K., et al. Stereotactic body radiotherapy for synchronous primary lung cancer: clinical outcome of 18 cases. Clin Lung Cancer 16 (2015), e91–e96.
11. 11 Takeda, T., Takeda, A., Kunieda, E., et al. Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol 182 (2004), 1123–1128.
12. 12 Dahele, M., Palma, D., Lagerwaard, F., et al. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 6 (2011), 1221–1228.
13. 13 Takeda, A., Kunieda, E., Ohashi, T., et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 141 (2012), 858–866.
14. 14 Ishijima, M., Nakayama, H., Itonaga, T., et al. Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy. Br J Radiol, 88, 2015, 20140596.
15. 15 Qiao, X., Tullgren, O., Lax, I., et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 41 (2003), 1–11.
16. 16 Takeda, A., Enomoto, T., Sanuki, N., et al. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy. Chest 143 (2013), 130–137.
17. 17 Palma, D., Lagerwaard, F., Rodrigues, G., et al. Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 82 (2012), 1149–1156.
18. 18 Matsuo, Y., Nagata, Y., Mizowaki, T., et al. Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol 12 (2007), 356–362.
19. 19 Shibamoto, Y., Hashizume, C., Baba, F., et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer 118 (2012), 2078–2084.
20. 20 Shibamoto, Y., Hashizume, C., Baba, F., et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol 10 (2015), 960–964.
21. 21 Baba, F., Shibamoto, Y., Tomita, N., et al. Stereotactic body radiotherapy for stage I lung cancer and small lung metastasis: evaluation of an immobilization system for suppression of respiratory tumor movement and preliminary results. Radiat Oncol, 4, 2009, 15.
22. 22 Takeda, A., Ohashi, T., Kunieda, E., et al. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol Biol Phys 77 (2010), 685–690.
23. 23 Wulf, J., Haedinger, U., Oppitz, U., et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60 (2004), 186–196.
24. 24 Song, D.Y., Benedict, S.H., Cardinale, R.M., et al. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 28 (2005), 591–596.
25. 25 Aviram, G., Yu, E., Tai, P., et al. Computed tomography to assess pulmonary injury associated with concurrent chemo-radiotherapy for inoperable non-small cell lung cancer. Can Assoc Radiol J 52 (2001), 385–391.
26. 26 Yamashita, H., Nakagawa, K., Nakamura, N., et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol, 2, 2007, 21.
27. 27 Rubin, P., Johnston, C.J., Williams, J.P., et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33 (1995), 99–109.
28. 28 Yamano, M., Ogino, H., Shibamoto, Y., et al. Relationship between radiation pneumonitis and prognosis in patients with primary lung cancer treated by radiotherapy. Kurume Med J 54 (2007), 57–63.
29. 29 Yamamoto, T., Jingu, K., Shirata, Y., et al. Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors. BMC Cancer, 14, 2014, 464.
30. 30 Baumann, P., Nyman, J., Hoyer, M., et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer—a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 88 (2008), 359–367.
31. 31 Lindberg, K., Nyman, J., Riesenfeld Källskog, V., et al. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT—the Nordic experience. Acta Oncol 27 (2015), 1–9.
32. 32 Huang, K., Senthi, S., Palma, D.A., et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol 109 (2013), 51–57.
33. 33 Mattonen, S.A., Palma, D.A., Haasbeek, C.J., Senan, S., Ward, A.D., Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. Med Phys, 41, 2014, 033502.
34. 34 Jochelson, M., Mauch, P., Balikian, J., et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 3 (1985), 637–640.
35. 35 Kaira, K., Murakami, H., Miura, S., et al. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 25 (2011), 247–253.
36. 36 Utsuki, S., Oka, H., Tanizaki, Y., et al. Histological features of intracranial germinomas not disappearing immediately after radiotherapy. Neurol Med Chir (Tokyo) 46 (2006), 429–433.
37. 37 Harwood, A.R., Krajbich, J.I., Fornasier, V.L., Radiotherapy of chondrosarcoma of bone. Cancer 45 (1980), 2769–2777.
38. 38 Miyakawa, A., Shibamoto, Y., Hashizume, C., et al. Early response and local control of stage I non-small-cell lung cancer after stereotactic radiotherapy: difference by histology. Cancer Sci 104 (2013), 130–134.
39. 39 Shibamoto, Y., Shibata, T., Miyatake, S., et al. Assessment of the proliferative activity and radiosensitivity of human tumours using the cytokinesis-block micronucleus assay. Br J Cancer 70 (1994), 67–71.
40. 40 Louie, A.V., Senan, S., Dahale, M., et al. Stereotactic ablative radiation therapy for subcentimeter lung tumors: clinical, dosimetric, and image guidance considerations. Int J Radiat Oncol Biol Phys 90 (2014), 843–849.
41. 41 Bush, K., Gagne, I.M., Zavgorodni, S., et al. Dosimetric validation of Acuros XB with Monte Carlo methods for photon dose calculations. Med Phys 38 (2011), 2208–2221.
42. 42 Latifi, K., Oliver, J., Baker, R., et al. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm. Int J Radiat Oncol Biol Phys 88 (2014), 1108–1113.
43. 43 Navarria, P., Ascolese, A.M., Mancosu, P., et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol 107 (2013), 414–418.
44. 44 Ferrero, C., Badellino, S., Filippi, A.R., et al. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study. Lung Cancer 89 (2015), 350–356.
45. 45 Kannarunimit, D., Descovich, M., Garcia, A., et al. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy. Technol Cancer Res Treat 14 (2015), 49–60.
46. 46 Huang, K., Dahele, M., Senan, S., et al. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)—can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 102 (2012), 335–342.
47. 47 Mattonen, S.A., Palma, D.A., Haasbeek, C.J., et al. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes. Acta Oncol 52 (2013), 910–918.